{"product_id":"henlius-business-model-canvas","title":"Shanghai Henlius Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Business Model Canvas: commercialization, R\u0026amp;D focus, revenue pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDive into Shanghai Henlius Biotech’s strategic playbook with our Business Model Canvas — a concise view of its value propositions, partner ecosystem, and commercialization pathways. This snapshot highlights revenue streams, cost structure, and R\u0026amp;D priorities to inform investment or strategic decisions. Purchase the full, editable Canvas (Word\/Excel) for a section-by-section roadmap you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma licensing allies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal pharma licensing allies co-develop and out-license Henlius biosimilars and biologics to expand reach; Henlius (2696.HK) leveraged partners to commercialize HLX02 (trastuzumab biosimilar) after NMPA approval in 2019 and EMA acceptance in 2020. Partnerships grant access to established brands, regulatory expertise and commercial infrastructures, share development risk, and accelerate entry into regulated and emerging markets, enabling indication expansion and lifecycle management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and clinical sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with leading CROs and tertiary hospitals to run coordinated multi-center trials, improving patient recruitment, data quality, and geographic diversity while ensuring ICH-GCP and regional regulatory compliance; this strategy aims to compress timelines across Phase I through post-marketing studies and accelerate evidence generation for regulatory submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Henlius secures high-quality cell lines, media, resins and single-use systems via preferred suppliers and validated QAs, supporting GMP continuity and cost efficiency; in 2024 Henlius reported revenue of RMB 2.5 billion reinforcing supplier leverage. The company uses CDMOs for surge capacity and specialized steps to accelerate launches and capex flexibility. Dual sourcing and contractual quality agreements reduce supply risk and protect manufacturing timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and tender agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius leverages national and provincial distributors and tender agents to secure hospital listings, navigating centralized procurement and complex tender timelines to maximize formulary access. Partnerships prioritize expansion into lower-tier Chinese cities and export markets while aligning pricing and reimbursement strategies with provincial tender outcomes. Demand forecasting is coordinated with distributors to optimize production and margin management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistributor networks: hospital listings\u003c\/li\u003e\n\u003cli\u003eTender navigation: centralized procurement\u003c\/li\u003e\n\u003cli\u003eGeographic expansion: lower-tier cities \u0026amp; exports\u003c\/li\u003e\n\u003cli\u003eCommercial ops: pricing, reimbursement, forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademia and technology partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Henlius leverages academia and tech partners to co-develop novel targets, assays and advanced analytics, accessing cutting-edge platforms such as high-throughput screening (\u0026gt;100,000 samples\/day) and AI-augmented CMC workflows that can cut development cycles by ~30%; IP is shared under clear licensing frameworks to expand the pipeline from biosimilars into innovative biologics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCollaborative target discovery\u003c\/li\u003e\n\u003cli\u003eHTS \u0026gt;100,000\/day\u003c\/li\u003e\n\u003cli\u003eAI-augmented CMC (~30% time reduction)\u003c\/li\u003e\n\u003cli\u003eClear IP licensing\u003c\/li\u003e\n\u003cli\u003ePipeline expansion: biosimilars → innovative biologics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar firm leverages global licensing and CDMO\/CRO partners, \u003cstrong\u003eRMB2.5bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius leverages global pharma licensing to commercialize biosimilars (HLX02: NMPA 2019, EMA 2020), partners with CROs and tertiary hospitals for multi-center trials, secures suppliers and CDMOs for GMP continuity and surge capacity, and uses distributors\/tender agents for hospital listings; 2024 revenue RMB 2.5 billion underpins partner leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eMarket access \u0026amp; out-license\u003c\/td\u003e\n\u003ctd\u003eHLX02 approvals; revenue base RMB 2.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Shanghai Henlius Biotech detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships aligned with its biologics development and commercialization strategy. Ideal for investor presentations, it includes competitive advantage analysis and linked SWOT insights to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Shanghai Henlius Biotech’s business model with editable cells, quickly pinpointing R\u0026amp;D, commercialization, and partnership gaps to relieve strategic planning and execution pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and optimize antibodies and fusion proteins, performing rigorous comparability for biosimilars and differentiation testing for novel assets; analytical, cell-based, and in vivo studies generate GLP\/GMP-grade data packages. Candidates progress through defined stage-gates with go\/no-go criteria, CMC comparability assessments, and regulatory-ready dossiers to support clinical and commercial milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExecute Phase I–III trials and extrapolation strategies across a diversified pipeline, with over 20 clinical studies and \u0026gt;6,000 patients enrolled by 2024. Manage pharmacokinetics, immunogenicity, and robust efficacy endpoints with centralized labs and CRO partnerships. Conduct risk management plans and real-world evidence programs; support global submissions across Asia, EU and US regulatory pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale upstream and downstream reliably across multi-10,000 L cGMP suites to support commercial supply; industry titers now routinely exceed 5 g\/L, enabling higher throughput. Validate processes, cleaning and aseptic ops with full qualification and batch‑level serialization for regulatory traceability. Maintain QA\/QC and batch release controls; process intensification has cut COGS by up to 30% in recent programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius prepares CTD dossiers and manages NMPA and global agency interactions to secure approvals and hospital\/NRDL listings, leveraging accelerated review pathways (median review timelines near 12 months in 2024) to speed market entry. It runs national tender and HTA-aligned pricing strategies—tender-driven price cuts ~50%—while handling reimbursement dossiers. Continuous pharmacovigilance monitors safety signals, compiles PSURs and risk management with dedicated PV teams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCTD preparation \u0026amp; agency liaison\u003c\/li\u003e\n\u003cli\u003eApprovals, NRDL\/listings, reimbursement\u003c\/li\u003e\n\u003cli\u003ePV, PSURs, signal management\u003c\/li\u003e\n\u003cli\u003ePricing tuned to tenders (~50% cuts) \u0026amp; HTA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial execution runs medical education and KAM engagement, manages hospital inclusion, tenders and distributor performance, executes patient support\/adherence programs, and forecasts demand with inventory control; China biologics market ~USD 40bn (2023) with biosimilars growing ~20% CAGR into 2024, driving intensified hospital tender activity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRun medical education \u0026amp; KAM\u003c\/li\u003e\n\u003cli\u003eManage hospital inclusion, tenders, distributors\u003c\/li\u003e\n\u003cli\u003ePatient support \u0026amp; adherence programs\u003c\/li\u003e\n\u003cli\u003eDemand forecasting \u0026amp; inventory management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale antibodies: \u0026gt;20 trials, \u0026gt;6,000 pts; multi-10k L, titers \u0026gt;5 g\/L, COGS -30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/optimize antibodies and biosimilars with GLP\/GMP comparability; run \u0026gt;20 clinical studies (\u0026gt;6,000 patients by 2024) across Phases I–III. Operate multi‑10,000 L cGMP suites, titers \u0026gt;5 g\/L, process intensification cutting COGS up to 30%. Secure approvals (median review ~12 months in 2024), tender pricing (~50% cuts) and NRDL\/reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical studies \/ patients\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20 \/ \u0026gt;6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecGMP scale \u0026amp; titers\u003c\/td\u003e\n\u003ctd\u003emulti-10,000 L \/ \u0026gt;5 g\/L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS reduction\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina biologics market\u003c\/td\u003e\n\u003ctd\u003e~USD 40bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory review median\u003c\/td\u003e\n\u003ctd\u003e~12 months (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTender price cuts\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Shanghai Henlius Biotech Business Model Canvas shown here is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, formatted and ready-to-edit. The full file is provided in Word and Excel formats for immediate use and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGMP manufacturing sites house bioreactors, automated fill-finish lines and accredited QC labs to deliver end-to-end biologics production. Qualified utilities and validated equipment maintain GMP compliance and traceability. Flexible capacity enables rapid multi-product campaigns. Integrated cold-chain (2–8°C distribution, −80°C storage) preserves product integrity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and clinical talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius leverages expert teams in cell line development, bioanalytical analytics, and clinical operations to support robust biologics pipelines. Cross-functional program management integrates R\u0026amp;D, CMC and clinical teams to shorten development timelines. Medical affairs translates clinical evidence into practice through physician engagement and real-world evidence generation. Regulatory specialists coordinate multi-jurisdictional filings and approvals across China, EU and US pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius protects platform process patents, trade secrets and validated analytical methods supporting platform mAb and Fc‑fusion development with scale demonstrated at 2,000 L bioreactors. Comparative data packages for biosimilars cover head‑to‑head analytical, PK and immunogenicity studies. Quality by Design frameworks are embedded across CMC to control critical quality attributes and ensure regulatory comparability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality systems and data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Henlius maintains robust QMS, LIMS and electronic batch records aligned to NMPA, FDA and EMA expectations, enabling traceable releases and audit readiness; pharmacovigilance, stability and RWE datasets underpin label claims and post‑market safety monitoring. Validated analytical libraries ensure comparability across biosimilar programs while secure, compliant data governance protects PHI and IP.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRobust QMS\/LIMS\/eBR\u003c\/li\u003e\n\u003cli\u003ePV, stability, RWE datasets\u003c\/li\u003e\n\u003cli\u003eValidated analytical libraries\u003c\/li\u003e\n\u003cli\u003eSecure, compliant governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to financing underpins Henlius’ ability to advance its biologics pipeline and expand manufacturing capacity, while strategic alliances with global partners extend commercialization reach across markets. Milestone-based economics from licensing deals provide recurring funding to support ongoing R\u0026amp;D, and government grants and tax incentives in China lower net development costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital: equity, venture, licensing\u003c\/li\u003e\n\u003cli\u003ePartnerships: regional distributors, global licensors\u003c\/li\u003e\n\u003cli\u003eMilestones: phased payments to fund R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003ePublic support: grants, tax incentives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP end-to-end biologics: \u003cstrong\u003e2,000 L\u003c\/strong\u003e manufacturing, automated fill-finish, \u003cstrong\u003e-80°C\u003c\/strong\u003e storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP sites with validated 2,000 L scale, automated fill‑finish and cold chain (2–8°C distribution, −80°C storage) enable end‑to‑end biologics supply. Robust QMS\/LIMS\/eBR, PV, stability and validated analytical libraries ensure comparability and audit readiness across NMPA, FDA and EMA. Capital from equity, licensing milestones and grants plus global partnerships fund pipeline and capacity expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e2,000 L scale; automated fill‑finish\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003e2–8°C distribution; −80°C storage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality \u0026amp; data\u003c\/td\u003e\n\u003ctd\u003eQMS\/LIMS\/eBR; PV, stability, RWE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing\u003c\/td\u003e\n\u003ctd\u003eEquity, licensing milestones, grants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordable high-quality biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius delivers cost-effective biosimilars proven to cut therapy prices by 20–70% versus originators, preserving clinical outcomes through rigorous quality and batch consistency. This expands access in oncology, autoimmune and ophthalmic care—supporting double-digit budget impact reductions for payers and broader patient uptake in 2024 markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable supply assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegrated in-house manufacturing minimizes shortages by consolidating production and quality control, while dual sourcing and inventory buffers ensure continuity across supply chains. Rigorous QA protocols reduce batch failures and rework, and validated cold-chain logistics preserve biologic efficacy from bulk drug substance to finished product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical comparability and evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHead-to-head and PK\/PD studies demonstrate equivalence within predefined 95% confidence intervals, building clinician confidence in interchangeability. Continuous immunogenicity monitoring via ADA surveillance programs tracks safety signals over time. Post-marketing real-world studies and registries reinforce performance across diverse populations and support reimbursement. Transparent regulatory dossiers streamline formulary review and procurement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpeed to market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEfficient development and disciplined regulatory execution compress Henlius time-to-market, enabling 3 rapid oncology and autoimmune indication expansions in 2024 that broadened patient reach across China and select APAC markets. Agile manufacturing platforms scale quickly post-approval to fulfill early tenders, capturing front-loaded share and supporting fast commercial rollouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpeed-to-market: 3 new indications in 2024\u003c\/li\u003e\n\u003cli\u003eRegulatory efficiency: shortened approval timelines vs prior cycles\u003c\/li\u003e\n\u003cli\u003eManufacturing agility: rapid scale-up for early tenders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and HCP support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient and HCP support programs combine education, adherence and affordability initiatives to improve outcomes and reduce discontinuation for complex biologics; Henlius supplements this with pharmacovigilance and 24\/7 medical information to ensure safety reporting and clinical guidance. Streamlined onboarding and switching services reduce time-to-therapy and enhance real-world effectiveness by coordinating reimbursement, logistics and nurse support.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducation: targeted HCP and patient materials\u003c\/li\u003e\n\u003cli\u003eAdherence: nurse follow-up and digital reminders\u003c\/li\u003e\n\u003cli\u003eAffordability: co-pay and access programs\u003c\/li\u003e\n\u003cli\u003eSafety: continuous pharmacovigilance and med-info\u003c\/li\u003e\n\u003cli\u003eOperational: onboarding, switching and infusion support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars cut costs \u003cstrong\u003e20-70%\u003c\/strong\u003e with resilient supply and \u003cstrong\u003e24\/7\u003c\/strong\u003e safety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius offers biosimilars reducing therapy costs 20–70% versus originators while preserving outcomes, expanding access in oncology, autoimmune and ophthalmic care; in 2024 it launched 3 new indications to capture early tender share. Integrated manufacturing and dual sourcing cut shortage risk and ensure batch consistency; continuous ADA surveillance, real-world registries and 24\/7 pharmacovigilance sustain clinician confidence and payer uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice reduction vs originator\u003c\/td\u003e\n\u003ctd\u003e20–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew indications (2024)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer impact\u003c\/td\u003e\n\u003ctd\u003eDouble-digit budget reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\u003c\/td\u003e\n\u003ctd\u003e24\/7 pharmacovigilance \u0026amp; med-info\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key account teams serve hospital groups and leading cancer centers, providing tailored contracting and supply planning that reduce stockouts and optimize oncology treatment continuity. Regular quarterly business reviews align commercial and clinical goals, while SLAs target rapid issue resolution to sustain long-term trust and preferred-partner status. Close collaboration drives improved patient access and institutional uptake of Henlius biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical engagement led by MSLs and advisory boards drives scientific exchange, delivering peer-reviewed evidence and clinician training to support guideline and pathway integration; in 2024 Henlius reinforced these non-promotional, compliant interactions to accelerate uptake of its oncology and immunology portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTender and procurement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoordinate bids, documentation and pricing strategies to support tender success, targeting a bid win rate \u0026gt;40% and standardized pricing playbooks in 2024. Ensure on-time delivery post-award with a 95%+ OTIF target and traceable shipment logs. Offer full compliance and audit readiness with 100% documentation retention for regulatory reviews. Maintain shared performance metrics with purchasers (monthly KPIs: fill rate \u0026gt;98%, SLA adherence).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient support services combine access assistance, co-pay relief and targeted education to reduce barriers to Henlius biologics, with nurse hotlines and digital adherence tools offering 24\/7 counseling and reminders; integrated pharmacovigilance follow-up captures safety signals and SAE reports for regulatory reporting, while closed-loop feedback from patients and HCPs continuously refines program design and resource allocation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess assistance: enrollment, prior authorization\u003c\/li\u003e\n\u003cli\u003eCo-pay relief: financial navigation\u003c\/li\u003e\n\u003cli\u003eEducation: disease + therapy modules\u003c\/li\u003e\n\u003cli\u003eNurse hotlines \u0026amp; digital adherence tools\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance follow-up\u003c\/li\u003e\n\u003cli\u003eFeedback loops for continuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital self-service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdigital self-service portals support ordering shipment tracking and secure documentation access enabling availability uptime slas for hcps pharmacists. e-learning modules deliver cme-aligned training with completion automated recalls safety alerts push immediate notifications to subscribed users. china internet penetration reached in supporting wide digital uptake.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortals: ordering, status, documentation\u003c\/li\u003e\n\u003cli\u003eE-learning: HCPs, pharmacists, completion tracking\u003c\/li\u003e\n\u003cli\u003eSafety: automated recalls, instant alerts\u003c\/li\u003e\n\u003cli\u003eAvailability: 24\/7 access, 99.9% SLA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMSL-led engagement lifts hospital uptake; portal SLA \u003cstrong\u003e99.9%\u003c\/strong\u003e, bid win \u0026gt;40%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams, MSL-led medical engagement and patient support programs drive hospital uptake and adherence; digital portals (99.9% SLA) and China internet penetration ~76% (2024) enable scale. Commercial targets: bid win rate \u0026gt;40%, OTIF 95%+, fill rate \u0026gt;98%; pharmacovigilance and feedback loops sustain trust and compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Target\/Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBid win rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTIF\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal uptime\u003c\/td\u003e\n\u003ctd\u003e99.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina internet\u003c\/td\u003e\n\u003ctd\u003e~76%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect hospital sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect hospital sales led by a field salesforce and KAMs focus on formulary inclusion, engaging drug and pharmacy therapeutic committees (DTCs, PTCs) and P\u0026amp;T reviews; China has over 34,000 hospitals (NHC 2023), so prioritization targets core tertiary centers. Sales teams coordinate with hospital pharmacies on demand planning and inventory replenishment to secure steady uptake and minimize stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational and regional distributors extend Henlius reach across China, targeting lower-tier cities that account for over 50% of the population to capture underserved demand. Cold-chain enforcement (typical biologic range 2–8°C) and strict SLAs (24–72 hour delivery windows) reduce product loss and ensure potency. Distributor contracts include enforceable KPIs and tiered incentives tied to on-time delivery, temperature compliance and post-sale service levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipate in centralized and provincial procurement to secure hospital and public-sector demand, meeting strict quality and volume commitments for biosimilars and oncology biologics. Align pricing to national reference and local competitive benchmarks to remain eligible for bulk tenders and maintain margin discipline. Strengthen presence through consistent on-time supply performance and post-market pharmacovigilance to win repeat procurements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLicense-out or co-market in overseas regions to accelerate Henlius product access, leveraging partners' regulatory dossiers and established sales networks; partners handle local registrations and distribution while Henlius retains manufacturing oversight. Share market intelligence and demand forecasts to align supply; coordinate cross-border pharmacovigilance for unified safety reporting and rapid signal response.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicense-out\/co-market\u003c\/li\u003e\n\u003cli\u003eLeverage regulatory \u0026amp; sales infrastructure\u003c\/li\u003e\n\u003cli\u003eShare market intelligence \u0026amp; forecasts\u003c\/li\u003e\n\u003cli\u003eCoordinate cross-border pharmacovigilance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and digital channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConferences, journals and webinars educate HCPs on Henlius pipelines and real-world data; CRM-enabled outreach personalizes content and follow-up; medical information hotlines answer safety and access queries; the company website (Henlius, listed on HKEX 2696 as of 2024) houses product resources and regulatory updates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConferences\u003c\/li\u003e\n\u003cli\u003eCRM outreach\u003c\/li\u003e\n\u003cli\u003eHotlines\u003c\/li\u003e\n\u003cli\u003eWebsite\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational hospital formulary push: 34,000 hospitals, distributors reach \u0026gt;50% population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect hospital sales target formulary inclusion across China’s 34,000 hospitals (NHC 2023) with KAMs coordinating pharmacy demand and inventory; distributors extend reach into lower-tier cities covering over 50% of the population; participate in centralized\/provincial procurement for bulk tenders; license-out\/co-market overseas while Henlius (HKEX 2696, 2024) retains manufacturing oversight.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eReach\/Fact\u003c\/th\u003e\n\u003cth\u003eKey KPI\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e34,000 hospitals (NHC 2023)\u003c\/td\u003e\n\u003ctd\u003eFormulary wins, stockouts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eLower-tier cities \u0026gt;50% pop\u003c\/td\u003e\n\u003ctd\u003eCold-chain SLA, OTIF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003eCentral\/provincial tenders\u003c\/td\u003e\n\u003ctd\u003ePrice eligibility, volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense-out\u003c\/td\u003e\n\u003ctd\u003eOverseas partners\u003c\/td\u003e\n\u003ctd\u003eRegulatory dossiers, PV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and cancer centers are the primary purchasers of infused and specialty biologics, with over 3,000 tertiary hospitals in China driving most oncology procurement in 2024. They prioritize predictable supply, consistent quality, and competitive pricing and require strict tender compliance and post-sale service. Hospital P\u0026amp;T committees and formularies heavily influence therapy adoption and market access, shaping volume and pricing outcomes across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists, rheumatologists and ophthalmologists drive over 60% of biologic prescribing relevant to Henlius’ portfolio, demanding robust phase III and real-world evidence plus clear switching guidance. They prioritize safety, efficacy and patient access, with formulary decisions increasingly tied to pharmacoeconomic data and reimbursement pathways. Engage them through targeted medical education, peer-reviewed registries and live-data dashboards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and procurement bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment agencies, insurers and GPOs (China basic medical insurance covers ~95% of the population in 2024) control reimbursement and procurement, demanding clear cost-effectiveness and supply reliability; national tenders and formularies can drive volumes. Centralized procurement rounds (2020–2024) cut prices by ~30–70% for many products, requiring thorough dossiers, real‑world data and periodic audits to secure listing and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational licensees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational licensees commercialize Henlius assets in ex-China markets, requiring reliable supply continuity, documented tech transfer and on-site training to meet regulatory and commercial timelines. Partnerships are structured with milestone payments plus running royalties to align incentives and accelerate market access. This model scales Henlius global footprint efficiently while preserving manufacturing control.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner role: ex-China commercialization\u003c\/li\u003e\n\u003cli\u003eNeeds: supply continuity, tech transfer, training\u003c\/li\u003e\n\u003cli\u003eFinancials: milestones + royalties\u003c\/li\u003e\n\u003cli\u003eGoal: efficient global footprint expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and advocacy groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and advocacy groups are the end beneficiaries of Henlius' accessible biologics, prioritizing affordability, adherence support, and demonstrable safety to reduce treatment gaps for oncology and autoimmune conditions.\u003c\/p\u003e\n\u003cp\u003eThey provide real-world insights on outcomes and unmet needs, reporting treatment discontinuation, side-effect concerns, and access barriers that guide Henlius' patient support programs and pharmacovigilance.\u003c\/p\u003e\n\u003cp\u003eAdvocacy partners amplify access and policy initiatives—engaging in reimbursement discussions, local guideline updates, and awareness campaigns that expand biosimilar uptake and equity in care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003efocus: affordability, adherence, safety\u003c\/li\u003e\n\u003cli\u003eroles: real-world outcome data, unmet-need reporting\u003c\/li\u003e\n\u003cli\u003eimpact: policy advocacy, reimbursement engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, clinicians and payers drive access as central procurement cuts prices 30–70%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary buyers: \u0026gt;3,000 tertiary hospitals (2024) prioritizing supply, quality, price; clinicians (oncologists\/rheum\/ophth) drive \u0026gt;60% prescribing and require Phase III\/RWE; payers\/GPOs cover ~95% population, central procurement cut prices 30–70%; ex-China partners use milestones+royalties to scale global access; patients demand affordability\/adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000 tertiary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e95% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical spend drives Henlius, with discovery, analytics and multi-phase trials consuming the bulk of outlays; the company reported roughly RMB 1.2 billion in R\u0026amp;D spending in 2023 and maintained similar pacing into 2024. CRO fees and site payments introduce program-level variability. Comparator drug procurement can add tens of millions RMB per biosimilar program. Post-marketing commitments sustain recurring clinical and safety costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedia, resins, consumables and utilities typically drive 30–40% of biologics COGS in 2024, with single‑use consumables increasing variable cost pressure. Depreciation on facilities and equipment commonly represents 15–25% of manufacturing cost due to recent capacity builds. Yield optimization can improve unit economics by 10–30% per process improvement. QC testing and release add 8–12% overhead, reflecting expanded analytic panels and release criteria.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory and quality costs cover submission preparation and dossier maintenance for NMPA\/WHO filings, routine and for-cause inspections, and enterprise-wide compliance systems to sustain market access. Pharmacovigilance operations and global safety databases drive ongoing signal detection and case management. Stability programs and validation ensure product integrity across shelf life. Audit readiness across the network requires continuous investment in SOPs, training, and corrective actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial and distribution costs for Shanghai Henlius center on a salesforce and medical affairs organization (education programs typically 8–12% of commercial spend) with average rep cost in China ~RMB 300,000 per year (2024); distributor margins run 15–25% and logistics\/cold-chain add ~3–7% of revenue, inventory holding absorbs ~8–12% of COGS, and tender participation can cost RMB 0.5–2.0M for major bids.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003esalesforce_cost:RMB 300k\/rep\/yr (2024)\u003c\/li\u003e\n\u003cli\u003emed_affairs_education:8–12% commercial spend\u003c\/li\u003e\n\u003cli\u003edistributor_margin:15–25%\u003c\/li\u003e\n\u003cli\u003ecold_chain_logistics:3–7% revenue\u003c\/li\u003e\n\u003cli\u003einventory_holding:8–12% COGS\u003c\/li\u003e\n\u003cli\u003etender_cost:RMB 0.5–2.0M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eG\u0026amp;A and partnerships at Shanghai Henlius allocate budget to corporate functions (finance, HR), IT infrastructure, and legal support to maintain compliance and secure commercialization pathways; IP prosecution and licensing fees are central to preserving biologics exclusivity, while alliance management teams coordinate co-development and out-licensing activities. Training and talent development focus on biologics R\u0026amp;D skills and regulatory affairs to support pipeline execution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eCorporate functions: finance, HR, IT, legal\u003c\/li\u003e\n\u003cli\u003eIP: prosecution, licensing fees\u003c\/li\u003e\n\u003cli\u003eAlliance management: partnership resourcing\u003c\/li\u003e\n\u003cli\u003eTraining: R\u0026amp;D, regulatory talent development\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D\/clinical ops cost hub — \u003cstrong\u003eRMB 1.2bn\u003c\/strong\u003e; unit cost save \u003cstrong\u003e10–30%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical ops dominate costs—RMB 1.2bn R\u0026amp;D in 2023, similar pacing into 2024, plus CRO\/site fees and comparator procurement per program.\u003c\/p\u003e\n\u003cp\u003eManufacturing COGS: consumables 30–40%, depreciation 15–25%, QC 8–12%; yield gains can cut unit cost 10–30%.\u003c\/p\u003e\n\u003cp\u003eCommercial G\u0026amp;A: rep cost ~RMB 300k\/yr, distributor margins 15–25%, cold-chain 3–7%, inventory 8–12% COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\/24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRep cost\u003c\/td\u003e\n\u003ctd\u003eRMB 300k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables (COGS)\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue derives from biosimilar and innovative biologics, with sales concentrated in hospital listings and public tenders driving price-volume dynamics. By 2024 Henlius marketed multiple biosimilars (eg HLX01 approved 2019) alongside innovative candidates, spanning oncology, autoimmune and ophthalmic indications. Volume growth is driven by expanded hospital access, tender wins and outpatient reimbursement coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius out-licenses assets to partners abroad, securing upfront payments that industry data show commonly range from USD 10–200 million per program and provide non-dilutive funding for R\u0026amp;D. Ongoing royalties, typically 5–15% of net sales in biologics deals, create long-term revenue streams tied to partner commercialization. Territory-specific agreements spread commercial and regulatory risk across regions, enhancing portfolio resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones and co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMilestone and co-development payments provide Henlius with staged income tied to development, regulatory and sales achievements, reducing upfront risk for the company. Shared R\u0026amp;D costs lower Henlius cash burn during expensive clinical phases and accelerate pipeline advancement. Option-based deal structures align partner incentives by letting collaborators choose follow-on rights based on data. This model supports sustained pipeline progression and capital efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Henlius leverages contract manufacturing by offering select CDMO services to partners, monetizing excess capacity and converting intermittent demand into stable fee-for-service income; the global biopharma CDMO market reached an estimated 25 billion USD in 2024, underscoring scalable upside for modular offerings like fill-finish and analytics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDMO services\u003c\/li\u003e\n\u003cli\u003eMonetize excess capacity\u003c\/li\u003e\n\u003cli\u003eFill-finish \/ analytics modules\u003c\/li\u003e\n\u003cli\u003eStable fee-for-service income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment incentives for Shanghai Henlius include grants, procurement premiums and R\u0026amp;D tax credits that help fund innovation and capacity building, offsetting R\u0026amp;D and capex outlays while being tied to compliance and performance metrics; China’s R\u0026amp;D super-deduction programs (commonly cited at up to 75% for qualified expenses) and municipal biotech grants materially lower effective costs in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eGrants: direct capex\/R\u0026amp;D support\u003c\/li\u003e\n\u003cli\u003eTax credits: up to 75% super-deduction\u003c\/li\u003e\n\u003cli\u003eProcurement premiums: price\/volume advantages\u003c\/li\u003e\n\u003cli\u003eConditional: compliance\/performance linked\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars growth via tenders, licensing and \u003cstrong\u003eUSD 25B\u003c\/strong\u003e CDMO market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue from biosimilars and innovative biologics via hospital listings, public tenders and outpatient reimbursement. By 2024 Henlius marketed multiple biosimilars (eg HLX01) and grows volume through tender wins. Licensing yields upfronts USD 10–200M and royalties of 5–15%. CDMO fees tap a USD 25B global market (2024) while R\u0026amp;D super-deduction up to 75% lowers effective costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003eUSD 25B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing upfront\u003c\/td\u003e\n\u003ctd\u003eUSD 10–200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D super-deduction\u003c\/td\u003e\n\u003ctd\u003eup to 75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097908318556,"sku":"henlius-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/henlius-business-model-canvas.png?v=1781796460","url":"https:\/\/pestel-analysis.com\/products\/henlius-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}